Should Ultrathin Strut Drug Eluting Stents Be Considered the New Benchmark for Novel Coronary Stents Approval? The Complex Interplay Between Stent Strut Thickness, Polymeric Carriers and Antiproliferative Drugs

Journal of Thoracic Disease - Hong Kong
doi 10.21037/jtd.2018.01.108
Full Text
Abstract

Available in full text

Date
Authors
Publisher

AME Publishing Company

Related search

Ultrathin Strut Biodegradable-Polymer Sirolimus-Eluting Stents: Being Wary or Going With the Flow?

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2018English

Biodegradable Polymer Evermine 50™ Everolimus Eluting Coronary Stent System With Ultrathin (50 Μm) Strut

Integrative Clinical Medicine
2018English

Drug-Eluting Stents

CMAJ
Medicine
2007English

Downstream Coronary Effects of Drug-Eluting Stents

American Heart Journal
Cardiovascular MedicineCardiology
2011English

Drug-Eluting Stents

CMAJ
Medicine
2007English

Stents Eluting 6-Mercaptopurine Reduce Neointima Formation and Inflammation While Enhancing Strut Coverage in Rabbits

PLoS ONE
Multidisciplinary
2015English

Should Dual Antiplatelet Therapy After Drug-Eluting Stents Be Continued for More Than 1 Year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely

Circulation: Cardiovascular Interventions
Cardiovascular MedicineCardiology
2008English

Late Stent Thrombosis in Drug-Eluting Stents: Return of the 'VB Syndrome'

Nature Clinical Practice Cardiovascular Medicine
2006English

Steroid-Eluting Stents in Patients With Acute Coronary Syndrome: The Dexamethasone Eluting Stent Italian REgistry

Heart
Cardiovascular MedicineCardiology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy